Table 1. Checkpoint inhibitors + chemotherapy: results

KN-189

Gandhi [17]

DDP + Pem + Pembro vs DDP + Pem

47.6 vs 18.9, p < 0.001

8.8 vs 17.5

8.8 vs 4.9, HR: 0.52, p = < 0.001

nr vs 11.3, HR: 0.49, p < 0.001

IMp-150

Socinski [91]

Atezo + Beva + CP vs Beva + CP

63.5 vs 48

5.1 vs 8.2

8.3 vs 6.8, HR: 0.62, p < 0.001

19.2 vs 14.7, HR: 0.78, p = 0.02*

IMp-130

West [19]

Atezo + CnP vs CnP

49.2 vs 31.9

11 vs 18.1

7 vs 5.5, HR: 0.64, p < 0.0001

18.6 vs 13.9, HR: 0.79, p = 0.033

IMp-132

Papadimitrakopoulou [92]

DDP + Pem + Atezo vs DDP + Pem

47 vs 32

–

7.6 vs 5.2, HR: 0.60,

p = < 0.0001

18.1 vs 13.6, HR: 0.81, p = 0.0797*

KN-407

Paz-Ares [18]

CP or CnP + Pembro vs CP or CnP

58.4 vs 35, p = 0.0004

6.9 vs 15.5

6.4 vs 4.8, HR: 0.56, p < 0.0001

15.9 vs 11.3, HR: 0.64, p = 0.0008

IMp-131

Jotte [93]

Atezo + CP vs Atezo + CnP vs CnP

(B) 49 vs (C) 41

–

6.3 vs 5.6, HR: 0.71, p = 0.0001

14 vs 13.9, HR: 0.96*, p = 0.6